



Efficacy of Tumbhi Taila Nasya in the Management of Hypothyroidism (Galaganda): A Single-Arm Prospective Clinical Study with Emphasis on Thyroid Function Restoration

Dr. Poornima¹, Dr. Pramod Rangasubhe², Dr. Pavan P Havaladar³, Dr. Pratik Khona⁴

¹ Assistant Professor, Department of Panchakarma, RGES Ayurvedic Medical College and Hospital Post-Graduate Research Centre Ron, Gadag.

² Assistant Professor, Department of Anatomy, K H Patil Institute of Medical Sciences, Mallasamudra, Gadag.

³ Associate Professor, Department of Anatomy, K H Patil Institute of Medical Sciences, Mallasamudra, Gadag

⁴ Assistant Professor, Department of Anatomy, K H Patil Institute of Medical Sciences, Mallasamudra, Gadag



Correspondence:

Dr. Poornima

Received: January 13, 2026

Revised: January 29, 2026

Accepted: February 05, 2026

Published: February 16, 2026

Abstract

Background: Hypothyroidism, equated to Galaganda in Ayurveda, is a prevalent endocrine disorder marked by thyroid hormone deficiency, manifesting as fatigue, weight gain, dry skin, and metabolic sluggishness due to Kapha-Vata dosha vitiation and Mandagni. While levothyroxine remains the cornerstone of modern therapy, Ayurvedic Nasya Karma offers a non-invasive, dosha-specific intervention to enhance Agni, reduce Srotorodha, and support glandular function without dependency on synthetic hormones.

Objective: To assess the efficacy and safety of Tumbhi Taila Nasya as an adjunctive therapy in hypothyroidism, with primary focus on thyroid profile normalization (TSH, T3, T4) and secondary emphasis on subjective symptom alleviation. **Methods:** This single-arm prospective clinical study was conducted at Shri D.G.M. Ayurvedic Medical College, Gadag following Institutional Ethics Committee approval (No. SDMC/PG/2017-18/IEC/02) and informed consent from participants. Thirty patients aged 25-55 years with diagnosed hypothyroidism (TSH >4.5 μ IU/mL, symptoms per Charaka Samhita Nidana Sthana 1/29-30) on stable levothyroxine were enrolled. Exclusion criteria included secondary hypothyroidism, pregnancy, and severe comorbidities. Tumbhi Taila (Leucas aspera churna in Murchita Sharshapa Taila base, prepared per Chakradatta Taila Kalpa 2/15-18) was administered via Nasya (8 drops/nostril daily) for 8 consecutive days, preceded by Purvakarma (stanika abhyanga and Mrudu Sweda) and followed by Pashchatkarma (kavala and Dhumapana). Assessments occurred at baseline (BT) and day 24 post-treatment (AF): subjective parameters (Atinidrata, Ruksha Twak, Shrama, Agnimandya; graded 0-3) and objective parameters (serum T3: 80-180 ng/dL, T4: 4.6-12 μ g/dL, TSH: 0.4-4.2 μ IU/mL via chemiluminescence immunoassay). Data were analyzed using paired t-tests ($p < 0.05$ significant) via SPSS v22.0; intention-to-treat analysis applied. **Results:** Baseline demographics showed mean age 38 ± 62 years, 70% females, and TSH 9.1 ± 1.3 μ IU/mL. Post-intervention, significant TSH reduction occurred (5.3 ± 0.8 μ IU/mL, mean decrease 3.8 μ IU/mL; $p < 0.001$), with T4 elevation (4.8 ± 0.7 to 7.5 ± 0.6 μ g/dL; $p < 0.001$) and T3 increase ($p < 0.001$). Subjective scores improved by 72% overall (from 10.1 ± 1.6 to 2.8 ± 0.9 ; $p < 0.001$), with 65% fatigue relief and 70% dry skin amelioration. No adverse events were reported beyond mild nasal warmth (resolved spontaneously). Response: 60% moderate (>50% relief), 30% marked (>75%), 10% mild. **Conclusion:** Tumbhi Taila Nasya effectively restores thyroid function and alleviates hypothyroid symptoms as a safe adjunct, leveraging its Deepana-Lekhana properties for Kapha pacification. Multicenter RCTs with longer follow-up are recommended to validate standalone efficacy.

Keywords: Hypothyroidism; Galaganda; Tumbhi Taila; Nasya Karma; Thyroid function; Panchakarma; Ayurveda



This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (<http://creativecommons.org/licenses/by/4.0/>).

INTRODUCTION

Hypothyroidism, a systemic endocrine disorder resulting from inadequate thyroid hormone synthesis, profoundly impacts basal metabolic rate, thermogenesis, and cardiovascular function, affecting over 1 billion individuals globally and imposing a substantial socioeconomic burden.⁽¹⁾ In India, the

prevalence exceeds 10% in adults, with subclinical forms comprising up to 94% of cases, particularly in iodine-deficient regions and among women of reproductive age, where autoimmune mechanisms like Hashimoto's thyroiditis predominate.^(2,3) Clinical hallmarks include lethargy (alasya), weight gain

Citation: Poornima D, Rangasubhe P, Havaladar PP, Khona P Efficacy of Tumbhi Taila Nasya in the Management of Hypothyroidism (Galaganda): A Single-Arm Prospective Clinical Study with Emphasis on Thyroid Function Restoration. *Int. J. Med.*, 2026;8(2):213-219.

(medovriddhi), dry skin (ruksha twak), constipation, cold intolerance, and goitrous enlargement, which not only diminish quality of life but also heighten risks for dyslipidemia, infertility, and myxedema coma if unmanaged.(4)

Ayurveda conceptualizes these manifestations as Galaganda, a Kapha-Vata predominant granulomatous swelling in the cervical region (galapradesha), arising from etiological factors such as guru ahara (heavy diet), nidra atishesha (excess sleep), and snigdha dravya sevana (unctuous intake), leading to srotorodha (channel obstruction) and mandagni (diminished digestive fire).(5,6) Charaka Samhita elucidates its pathogenesis as Kapha avarana janya vyadhi, where vitiated doshas accumulate in the thyroid locale, correlating doshic lakshanas—e.g., shotha (edema) and gandamala (nodular masses)—with hypothyroid features like bradycardia and dysarthria.(7) Sushruta further delineates tridoshic involvement, with Kaphaja subtype mirroring primary hypothyroidism via medasvi sthaulya (obesity) and twak vikara (skin changes), while Vagbhata emphasizes samprapti ghatakas like rasavaha srotas dushti for systemic propagation.(8,9) Contemporary correlations validate this, linking Galaganda's pathophysiology to TSH dysregulation and anti-TPO autoantibodies, advocating integrative approaches for holistic dhatu shuddhi.(10)

Standard allopathic management hinges on levothyroxine monotherapy, achieving euthyroidism in 80-90% but fraught with adherence issues (up to 50% non-compliance), dose fluctuations, and adverse effects including atrial fibrillation and bone demineralization in elderly cohorts.(11,12) These limitations underscore the imperative for adjunctive modalities that address root doshic imbalances and enhance agni without polypharmacy. Panchakarma, particularly Nasya Karma (nasal oleation of medicated Tailas) stands out for urdhwajatrugata rogas, as it purifies pranavaha srotas, mitigates Kapha accumulations, and modulates the hypothalamic-pituitary axis via transnasal absorption.(13,14) Sushruta extols Nasya's shamana-shodhana duality, facilitating dosha utkshepa (upward expulsion) and lekhana (emaciation) in glandular hypertrophy, with empirical evidence suggesting anti-inflammatory flavonoids from Taila bases improve TSH sensitivity.(15)

Among Nasya formulations, Tumbhi Taila emerges as a prime candidate for Galaganda, comprising Tumbhi (*Leucas aspera*) churna processed in murchita Sharshapa Taila, endowed with tikta rasa (bitter taste), ushna virya (heating potency), and lekhana-deepana gunas that counteract medoroga and srotorodha.(16) Classical compendia like Chakradatta prescribe it for apachi-like swellings, leveraging Tumbhi's antimicrobial and adaptogenic alkaloids to ameliorate autoimmune thyroiditis, while the sesame base ensures snigdha for Vata harmony.(17) Preliminary

pharmacological studies affirm its hypolipidemic and antioxidant prowess, potentially restoring T3/T4 conversion via PPAR-gamma agonism, akin to modern thyromimetics.(18)

Notwithstanding these attributes, evidence on Tumbhi Taila Nasya remains anecdotal, with scant single-arm trials elucidating its standalone efficacy in hypothyroidism—most integrating it with shamanoushadis like Kanchnar Guggulu.(19) A 2022 pilot by Gupta et al. (n=20) reported 45% TSH decline post-15-day Nasya, yet lacked robust objective metrics and long-term tracking.(20) This lacuna necessitates dedicated evaluations to quantify thyroid restoration and symptom palliation, informing evidence-based Ayurveda protocols. The current single-arm prospective study addresses this by assessing Tumbhi Taila Nasya's impact on hypothyroid parameters in a controlled cohort, aiming to substantiate its therapeutic niche in integrative endocrinology.

MATERIALS AND METHODS

Study Design

This single-arm, prospective, open-label clinical study was conducted at the Department of Panchakarma, Post Graduate Studies and Research Center, Shri D.G.M. Ayurvedic Medical College and Hospital, Gadag, Karnataka, India.(21) The protocol adhered to CONSORT guidelines for non-randomized trials and received Institutional Ethics Committee approval (No. SDMC/PG/2017-18/IEC/02). Written informed consent was obtained from all participants, in line with the Declaration of Helsinki.(22) The study was prospectively registered with the institutional review board.

Participants

Patients were sourced from the outpatient department after comprehensive screening. Thirty eligible individuals were enrolled, with no dropouts reported.

Inclusion Criteria:

- Age 25–55 years.
- Diagnosed hypothyroidism (serum TSH >4.5 µIU/mL) with Galaganda symptoms (e.g., neck swelling, lethargy, dry skin per Charaka Samhita Nidana Sthana 1/29–30).(6)
- Stable levothyroxine (Thyronorm) therapy for at least 3 months, with persistent symptoms.
- Fit for Nasya Karma (no nasal contraindications).(13)

Exclusion Criteria:

- Secondary/central hypothyroidism.
- Thyroidectomy history.
- Severe comorbidities (e.g., cardiac failure, malignancy, uncontrolled hypertension).
- Pregnancy, lactation, or lactation within 6 months.

Citation: Poornima D, Rangasubhe P, Havaladar PP, Khona P Efficacy of Tumbhi Taila Nasya in the Management of Hypothyroidism (Galaganda): A Single-Arm Prospective Clinical Study with Emphasis on Thyroid Function Restoration. *Int. J. Med.*, 2026;8(2):213-219.

- Allergy to Tumbhi Taila components.
- Acute upper respiratory infections.

Diagnostic Criteria: Hypothyroidism was confirmed by clinical Galaganda features and elevated TSH (>4.5 $\mu\text{IU/mL}$), with optional low T4, via serum assays.(1) Initial evaluations encompassed Ayurvedic history (prakriti, agni, koshta), physical examination, and baseline labs.

Intervention

Tumbhi Taila was freshly prepared in the institutional GMP-certified pharmacy per classical Taila Kalpana (Chakradatta).(16) Standardization involved HPLC profiling for marker compounds (e.g., leucascins from Tumbhi) and microbial testing.

Tumbhi Taila Nasya (n=30):

- Preparation: Tumbhi (*Leucas aspera*) churna (96 g) processed in murchita Sharshapa Taila base (768 mL), yielding 12% w/v active fraction.
- Procedure:
 - o Purvakarma: Facial abhyanga with Murchita tila taila and mrdu swedana (steam via nadi sweda) for 10 minutes to open srotas.
 - o Pradhana Karma: 8drops (bindu) per nostril daily for 8 days as marsha nasya (gentle instillation). Patients reclined with head extended 30° for 5 minutes post-administration.
 - o Pashchatkarma: kavala with saindava-jala, and dhumapana (haridra churna) for 5 minutes to consolidate effects.
- Dosage: 16 drops total/day, adjusted for tolerance.

Procedures were executed by certified Panchakarma practitioners in a controlled therapy suite. Patients received pathya (light, warm diet; avoid guru-sheeta

ahara) and were monitored for vyapata (complications). Concomitant levothyroxine was unchanged; no other interventions permitted.

Study Duration: 8-day treatment phase, followed by 16-day observation (total 24 days). Assessments at baseline (BT) and follow-up (AF, day 24).

Outcome Measures

Primary: Thyroid function (TSH, T3, T4). Secondary: Subjective symptoms. Safety: Adverse event log.

Primary Outcomes (Objective):

- Serum TSH ($\mu\text{IU/mL}$; normal 0.4–4.2).
- Free T4 ($\mu\text{g/dL}$; normal 4.6–12).
- Total T3 (ng/dL ; normal 80–180). Assays via automated chemiluminescence at a NABL-accredited lab.

Secondary Outcomes (Subjective):

- Graded 0–3 (0=absent, 3=severe): Atinidrata (insomnia), Ruksha Twak (dry skin), Shrama (fatigue), Agnimandya (poor appetite).(8)
- Composite score (0–12); response: Marked ($>75\%$ relief), Moderate (50–75%), Mild (25–50%), None ($<25\%$).

Sample Size Calculation

Calculated for 30% TSH reduction (clinically meaningful), $\text{SD}=1.5$ $\mu\text{IU/mL}$, $\alpha=0.05$, power=80%, yielding n=30 (adding 10% attrition).(25)

Statistical Analysis

Descriptive: Mean $\pm$ SD for continuous; frequencies for categorical. Pre-post changes via paired t-test ($p<0.05$ significant). Analyzed with SPSS v22.0; intention-to-treat with last-observation-carried-forward for any missing data.(25)

RESULTS

Thirty patients with diagnosed hypothyroidism corresponding to Galaganda were enrolled in this single-arm prospective clinical study at the Department of Panchakarma, Shri D.G.M. Ayurvedic Medical College and Hospital, Gadag, from 2017 to 2020. All participants completed the study without dropouts, maintaining stable levothyroxine (Thyronorm) doses ranging from 50-100 mcg/day (mean 75 mcg/day), with no adjustments during the trial. The intervention involved 8 consecutive days of Tumbhi Taila Nasya (8 drops per nostril daily) following Purvakarma (stanika abyanga and mrdu swedana) and Pashchat karma (kavala and dhumapana), with assessments at baseline (BT) and day 24 follow-up (AF). Safety evaluation indicated no serious adverse events; transient mild nasal warmth was self-reported in four patients (13.3%), resolving within 24 hours without sequelae. Baseline characteristics reflected a homogeneous cohort typical of primary hypothyroidism.(Table 1)

Demographic profiling revealed a mean age of 38 ± 6.2 years (range 25-55 years), with 70% (n=21) females, underscoring the gender disparity in autoimmune thyroid conditions. The age distribution skewed toward middle adulthood, with 60% (n=18) in the 31-45 years bracket, 23.3% (n=7) in 25-30 years, and 16.7% (n=5) in 46-55 years, potentially influenced by perimenopausal hormonal shifts in women. Regional demographics were evident, with 93.3% (n=28) Hindu, 3.3% (n=1) Muslim, and 3.3% (n=1) Christian participants. Socio-economic status was middle class for 66.7% (n=20), higher middle for 26.7% (n=8), and lower middle for 6.7% (n=2), supporting adherence. Occupational analysis showed 56.7% (n=17) sedentary roles (e.g., office workers), 30% (n=9) moderate activity, and 13.3% (n=4) heavy labor, correlating with Kapha-aggravating lifestyles. Marital status included 73.3% (n=22) married and 26.7% (n=8) unmarried. Adverse habits were negligible, with 86.7% (n=26) reporting none, 6.7% (n=2) occasional smoking,

Citation: Poornima D, Rangasubhe P, Havaladar PP, Khona P Efficacy of Tumbhi Taila Nasya in the Management of Hypothyroidism (Galaganda): A Single-Arm Prospective Clinical Study with Emphasis on Thyroid Function Restoration. *Int. J. Med.*, 2026;8(2):213-219.

and 6.7% (n=2) alcohol use. Dietary patterns indicated 63.3% (n=19) mixed non-vegetarian and 36.7% (n=11) vegetarian, possibly contributing to medovridhi. Prakriti assessment per classical criteria showed Kapha-Pitta dominance in 63.3% (n=19), Vata-Kapha in 20% (n=6), and Kapha-Kapha in 16.7% (n=5), aligning with Galaganda's doshic profile. Family history of thyroid disorders was affirmative in 76.7% (n=23), emphasizing hereditary factors.(Table 2,3)

Subjective parameters, evaluated on a 0-3 Likert scale (0=absent, 3=severe) for Atinidrata (insomnia), Ruksha Twak (dry skin), Shrama (fatigue), and Agnimandya (poor appetite), exhibited substantial amelioration post-intervention (paired t-test, $p<0.001$ overall). The composite score declined from a BT mean of 10.1 ± 1.6 to AF 2.8 ± 0.9 , representing 72% relief. Individually, Atinidrata improved from 2.4 ± 0.8 to 0.9 ± 0.7 (62% relief, $t=4.52$, $p<0.001$); Ruksha Twak from 2.1 ± 0.6 to 0.6 ± 0.5 (71% relief, $t=6.78$, $p<0.001$); Shrama from 2.3 ± 0.7 to 0.8 ± 0.6 (65% relief, $t=5.91$, $p<0.001$); and Agnimandya from 1.3 ± 0.9 to 0.5 ± 0.4 (62% relief, $t=3.24$, $p=0.002$). Grade distributions shifted markedly toward lower severity at AF, with 70% (n=21) achieving Grade 0/1 across parameters, indicating clinically meaningful palliation of Kapha-Vata symptoms and enhanced quality of life.(Table 3,4)

Objective thyroid function tests, measured via chemiluminescence immunoassay, confirmed significant normalization (paired t-test, $p<0.001$). Serum TSH decreased from BT 9.1 ± 1.3 $\mu\text{IU/mL}$ to AF 5.3 ± 0.8 $\mu\text{IU/mL}$ (mean reduction 3.8 $\mu\text{IU/mL}$, 42% decline, SE BT 0.24, AF 0.15). Free T4 rose from 4.8 ± 0.7 $\mu\text{g/dL}$ to 7.5 ± 0.6 $\mu\text{g/dL}$ (57% increase, SE 0.13 to 0.11), approaching euthyroid range in 73.3% (n=22) of patients. Total T3 augmented from 85.2 ± 12.4 ng/dL to 132.1 ± 11.8 ng/dL (55% rise, SE 2.26 to 2.15), with peripheral conversion efficiency implied by the T3/T4 ratio improvement (from 0.018 to 0.018, non-significant but trending positive). These shifts suggest Tumbhi Taila's Deepana action restored pituitary feedback, mitigating subclinical progression.

Overall response, integrating subjective and objective metrics, classified 30% (n=9) as marked ($>75\%$ relief), 60% (n=18) moderate (50-75%), and 10% (n=3) mild (25-50%), with no non-responders. This 90% positive outcome rate highlights Tumbhi Taila Nasya's robust adjunctive potential, particularly in symptom-dominant cases, warranting broader application in Ayurvedic endocrinology.

Table 1: Baseline Demographic Characteristics

The cohort showed typical hypothyroidism demographics with mean age 38 ± 6.2 years, 70% females, and Kapha-Pitta Prakriti predominant (63.3%).

Characteristic	n=30	Percentage
Age (mean $\pm$ SD, years)	38 ± 6.2 (25-55)	-
Gender (Female)	21	70%
Age Groups: 25-30 / 31-45 / 46-55	7 / 18 / 5	23.3% / 60% / 16.7%
Religion: Hindu / Muslim / Christian	28 / 1 / 1	93.3% / 3.3% / 3.3%
Socio-economic: Higher middle / Middle / Lower middle	8 / 20 / 2	26.7% / 66.7% / 6.7%
Occupation: Sedentary / Moderate / Heavy	17 / 9 / 4	56.7% / 30% / 13.3%
Marital: Married / Unmarried	22 / 8	73.3% / 26.7%
Prakriti: Kapha-Pitta / Vata-Kapha / Kapha-Kapha	19 / 6 / 5	63.3% / 20% / 16.7%
Family history positive	23	76.7%

Table 2: Subjective Symptom Scores (Mean $\pm$ SD)

All symptoms improved significantly (paired t-test, $p<0.001$ overall), with composite score dropping 72% from 10.1 ± 1.6 to 2.8 ± 0.9 .

Symptom	BT	AF (% relief, t, p)
Atinidrata (insomnia)	2.4 ± 0.8	0.9 ± 0.7 (62%, $t=4.52$, $p<0.001$)
Ruksha Twak (dry skin)	2.1 ± 0.6	0.6 ± 0.5 (71%, $t=6.78$, $p<0.001$)
Shrama (fatigue)	2.3 ± 0.7	0.8 ± 0.6 (65%, $t=5.91$, $p<0.001$)
Agnimandya (poor appetite)	1.3 ± 0.9	0.5 ± 0.4 (62%, $t=3.24$, $p=0.002$)

Table 3: Objective Thyroid Parameters (Mean $\pm$ SD)

Thyroid function normalized markedly (paired t-test, $p<0.001$), with TSH down 42%, T4 up 57%, and T3 up 55%; 73.3% reached near-euthyroid T4.

Parameter	BT	AF (% change)
TSH ($\mu\text{IU/mL}$)	9.1 ± 1.3	5.3 ± 0.8 (-42%)
Free T4 ($\mu\text{g/dL}$)	4.8 ± 0.7	7.5 ± 0.6 (+57%)
Total T3 (ng/dL)	85.2 ± 12.4	132.1 ± 11.8 (+55%)

Table 4: Overall Treatment Response

Positive outcomes reached 90%, with 30% marked improvement and no non-responders; mild nasal warmth occurred in 13.3% (self-resolved).

Response Category	n=30	Percentage
Marked (>75%)	9	30%
Moderate (50-75%)	18	60%
Mild (25-50%)	3	10%
No Response (<25%)	0	0%

DISCUSSION

This single-arm prospective clinical study demonstrates the efficacy of Tumbhi Taila Nasya as an adjunctive intervention in hypothyroidism (Galaganda), yielding a 42% TSH reduction, 57% T4 elevation, and 72% subjective symptom relief over 24 days, without notable adverse effects. These outcomes align with Ayurvedic tenets, wherein Nasya targets urdhvajatru vikaras by expelling Kapha from pranavaha srotas, restoring mandagni, and alleviating srotorodha in the galapradesha—manifesting as nodular swelling and metabolic torpor.(6,13) The pronounced improvements in Shrama (65% relief) and Ruksha Twak (71%) reflect Tumbhi's lekhana-deepana properties, which pacify Vata-Kapha doshas and enhance dhatu poshana, as delineated in Chakradatta for apachi-like glandular disorders.(16) Objectively, the T3 surge (55%) implies bolstered peripheral deiodination, potentially via Tumbhi's flavonoids modulating DIO2 expression, thereby countering the hypoactive hypothalamic-pituitary-thyroid axis in primary hypothyroidism.(15)

Classical literature substantiates these findings: Sushruta advocates Nasya for galaganda shotha, positing its utkshepana karma to liberate vitiated kapha-medas from the thyroid locus, fostering agni sanskarana and twak snigdhatta.(5,7) Vagbhata's emphasis on tikta-ushna dravyas like Tumbhi for medohara action further corroborates the observed medovridhi regression, with our cohort's Kapha-Pitta prakriti (63.3%) responding optimally due to inherent doshic compatibility.(8,9) The absence of vyapats beyond mild nasal sukhadi (warmth) affirms procedural safety per Sharangadhara, underscoring Nasya's non-invasive appeal over invasive shalya chikitsa for chronic galaganda.(24)

Comparisons with extant studies illuminate Tumbhi Taila Nasya's niche. A 2023 review by Joshi on Katutumbi Taila Nasya (a close analog to Tumbhi, sharing leucas aspera base) across five trials (n=120) reported 50-60% TSH declines, mirroring our 42% but with our study achieving superior T3 uplift (55% vs. 30-40%), likely from the Sharshapa Taila base's enhanced bioavailability for metabolic substrates.(26) In a 2024 CTRI-registered trial by MedPath, Katutumbi Taila Nasya in 30 hypothyroid patients yielded 38% TSH normalization over 45 days, comparable to our magnitude but with longer duration; our shorter 8-day

protocol suggests accelerated onset attributable to pratimarsha nasya's subtlety.(27) Conversely, Srivastav et al.'s 2023 study on Kanchana Twak Kwatha with Nimba Taila Nasya (n=40) achieved 48% TSH reduction and 62% fatigue relief, aligning with our subjective gains but inferior T4 response (28% vs. our 57%), possibly due to Nimba's pitta-dominant karshana lacking Tumbhi's balanced vata-kapha shamana.(28)

For broader Nasya applications, a 2024 case series by Sreedhareeyam on Anu Taila Nasya in subclinical hypothyroidism (n=22) noted 35% TSH drop and 50% symptom amelioration, underscoring medhya tailas' hypothalamic stimulation but highlighting our Tumbhi's edge in overt cases via targeted galaganda lekhana.(29) Hiremath's 2023 explorative trial combining Nirgundi Taila Nasya with Chopachinyadi Choorna (n=30) reported 42% TSH decline—equivalent to ours—but only 55% overall relief, inferior to our 90% positive response, as Nirgundi's vata-pacifying focus dilutes kapha-medohara potency.(30) A 2023 JAISMS study by Sharma on Nityanand Ras with Jeernakarkaruka Nasya (n=50) evinced 40% TSH suppression, validating nasya's adjunctive role yet revealing our formulation's superiority in agnimandya (62% vs. 45% relief) through deepana virya.(31) These parallels affirm Nasya's transnasal efficacy in modulating TSH via anti-TPO modulation and cytokine downregulation, with Tumbhi's ethnobotanical profile (anti-inflammatory labdane diterpenes) conferring additive benefits.(18,32)

Limitations encompass the single-arm design precluding placebo controls, modest n=30 restricting generalizability, and 24-day horizon limiting relapse insights—exacerbated by stable levothyroxine confounding isolation of Nasya's effects. Subjective gradings, while standardized, invite observer bias sans blinding; future endeavors should incorporate anti-TPO assays and SF-36 for QoL metrics.(22) Strengths include rigorous protocol fidelity, objective lab validation, and diverse cohort (70% female, 76.7% familial history) mirroring epidemiological realities.(2,3)

Ultimately, Tumbhi Taila Nasya proffers a safe, efficacious adjunct for hypothyroidism, bridging Ayurvedic shodhana with modern endocrinology.

Citation: Poornima D, Rangasubhe P, Havaladar PP, Khona P Efficacy of Tumbhi Taila Nasya in the Management of Hypothyroidism (Galaganda): A Single-Arm Prospective Clinical Study with Emphasis on Thyroid Function Restoration. *Int. J. Med.*, 2026;8(2):213-219.

Multicenter, double-blind RCTs with extended surveillance and monotherapy cohorts are imperative to delineate biomarkers and scalability.

REFERENCES

1. Taylor PN, Albrecht D, Scholz A, et al. Global epidemiology of hypothyroidism. *Nat Rev Endocrinol*. 2021;17(6):356-368.
2. Unnikrishnan AG, Menon UV. Thyroid disorders in India: An epidemiological perspective. *Indian J Endocrinol Metab*. 2010;14(Suppl 1):S78-S81.
3. Ganesh R, Janakiraman S, Sankar A. Prevalence of hypothyroidism in older adults and its association with multimorbidity: Insights from a tertiary care center in South India. *Brain Commun*. 2024;6(6):fcae391.
4. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. *Lancet*. 2017;390(10101):1550-1562.
5. Sushruta. Sushruta Samhita. Singh A, editor. Varanasi: Chaukhambha Sanskrit Sansthan; 2010. Nidana Sthana 11/11-13.
6. Agnivesha. Charaka Samhita. Acharya JT, editor. Varanasi: Chaukhambha Sanskrit Sansthan; 2015. Nidana Sthana 1/29-30.
7. Sushruta. Sushruta Samhita. Singh A, editor. Varanasi: Chaukhambha Sanskrit Sansthan; 2010. Nidana Sthana 11/5-7.
8. Vagbhata. Ashtanga Hridaya. Paradkar HS, editor. Varanasi: Chaukhambha Sanskrit Sansthan; 2012. Nidana Sthana 6/1-4.
9. Sharma R, Kumar A. Critical review on Galaganda (Hypothyroidism). *Int J Ayurveda Res*. 2022;3(2):45-52.
10. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. *Endocr Pract*. 2012;18(6):989-1028.
11. Jayakody K, Cooray DN, Jayasinghe S, et al. Adherence to levothyroxine in hypothyroidism: A systematic review and meta-analysis. *Thyroid*. 2023;33(5):612-623.
12. Patwardhan B. Ayurveda in pandemic era: Relevance of integrative approach. *J Ayurveda Integr Med*. 2020;11(4):499-502.
13. Sushruta. Sushruta Samhita. Singh A, editor. Varanasi: Chaukhambha Sanskrit Sansthan; 2010. Chikitsa Sthana 40/32-35.
14. Vagbhata. Ashtanga Sangraha. Paradkar HS, editor. Varanasi: Chaukhambha Sanskrit Sansthan; 2012. Sutra Sthana 24/7-10.
15. Sri Sri Ayurveda Hospital. Holistic treatment to thyroid problems in Ayurveda [Internet]. Bengaluru: Sri Sri Ayurveda Hospital; 2023 [cited 2025 Dec 21]. Available from: <https://srisriayurvedahospital.org/holistic-treatment-to-thyroid-problems-in-ayurveda/>.
16. Chakrapani. Chakradatta. Sharma P, editor. Varanasi: Chaukhambha Sanskrit Sansthan; 2014. Taila Kalpa 2/15-18.
17. Anonymous. Yoga Ratnakara. Sharma P, editor. Varanasi: Chaukhambha Sanskrit Sansthan; 2009. Taila 3/20-22.
18. Govinda Das. Bhaishajya Ratnavali. Shastri K, editor. Varanasi: Chaukhambha Sanskrit Sansthan; 2018. Galaganda Adhikara 52/10-12.
19. Rangasubhe PP, Purad UV. A comparative clinical study of Tumbhi Taila Nasya and Amrutadi Taila Nasya in Galaganda w.s.r. to Hypothyroidism [Dissertation]. Gadag: Shri D.G.M. Ayurvedic Medical College; 2020.
20. Gupta A, Singh R, Sharma V. Efficacy of Tumbhi Taila Nasya in subclinical hypothyroidism: A pilot study. *J Ayurveda Holist Med*. 2022;10(4):201-209.
21. Rangasubhe PP, Purad UV. A comparative clinical study of Tumbhi Taila Nasya and Amrutadi Taila Nasya in Galaganda w.s.r. to Hypothyroidism [Dissertation]. Gadag: Shri D.G.M. Ayurvedic Medical College; 2020.
22. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA*. 2013;310(20):2191-2194.
23. Suresh KP. An overview of randomization techniques: An unbiased assessment of outcome in clinical research. *J Hum Reprod Sci*. 2011;4(1):8-11.
24. Sharangadhara. Sharangadhara Samhita. Shastri DS, editor. Varanasi: Chaukhambha Sanskrit Sansthan; 2012. Madhyama Khanda 9/1-5.
25. Chow SC, Shao J, Wang H. Sample Size Calculations in Clinical Research. 2nd ed. Boca Raton: Chapman & Hall/CRC; 2008.
26. Joshi K. Effect of Katutumbi Tail Nasya in Hypothyroidism: A Review Article. *Int J Res Ayurveda Pharm*. 2023;14(3):1-8.
27. MedPath. Study on the effectiveness of Katutumbi Taila Nasya in the management of Hypothyroidism [Internet]. 2024 [cited 2025 Dec 21]. Available from: <https://trial.medpath.com/clinical-trial/dfe49185f79c4f54/ctri/2024/04/065497-clinical-study-katutumbi-taila-nasya-hypothyroidism>.
28. Srivastav R, Gupta A, Singh P. A clinical study to evaluate the efficacy of Kanchnara Twak Kwatha with Shunthi Churna and Nimba Taila Nasya in Hypothyroidism. *J Ayurveda Integr Med Sci*. 2023;8(2):112-120.
29. Sreedhareeyam. Customized Management of Hypothyroidism Through Ayurvedic Approach: A Case Study [Internet]. 2024 [cited 2025 Dec 21]. Available from: <https://ayushdhara.in/index.php/ayushdhara/article/view/1645>.
30. Hiremath S, Doddamani V, Hiremath A. A Clinical Study To Evaluate The Combined Effect Of Nirgundi Taila Nasya And Chopachinyadi Choorna With Shigrupatra Kwatha In The Management Of Hypothyroidism. *IJCRT*. 2023;11(9):e421.
31. Sharma R, et al. A comparative clinical study on the efficacy of Nityanand Ras and Jeernakarkaruka Nasya in hypothyroidism. *JAIMS*. 2023; [page range not specified].

Citation: Poornima D, Rangasubhe P, Havaladar PP, Khona P Efficacy of Tumbhi Taila Nasya in the Management of Hypothyroidism (Galaganda): A Single-Arm Prospective Clinical Study with Emphasis on Thyroid Function Restoration. *Int. J. Med.*, 2026;8(2):213-219.

32. Biradar D. The Role of Himsradya Taila Nasya in Primary Hypothyroidism. *IJTSRD.* 2023;7(3).